Abstract

Optimal treatment for recurrent glioblastoma isocitrate dehydrogenase 1 and 2 wild-type (rGBM IDH-WT) is not standardized, resulting in multiple therapeutic approaches. A phase III clinical trial showed that tumor treating fields (TTFields) monotherapy provided comparable survival benefits to physician's chemotherapy choice in rGBM. However, patients did not equally benefit from TTFields, highlighting the importance of identifying predictive biomarkers of TTFields efficacy.A retrospective review of an institutional database with 530 patients with infiltrating gliomas was performed. Patients with IDH-WT rGBM receiving TTFields at first recurrence were included. Tumors were evaluated by next-generation sequencing for mutations in 205 cancer-related genes. Post-progression survival (PPS) was examined using the log-rank test and multivariate Cox-regression analysis.149 rGBM patients were identified of which 29 (19%) were treated with TTFields. No significant difference in median PPS was observed between rGBM patients who received versus did not receive TTFields (13.9 versus 10.9 months, p?=?0.068). However, within the TTFields-treated group (n?=?29), PPS was improved in PTEN-mutant (n?=?14) versus PTEN-WT (n?=?15) rGBM, (22.2 versus 11.6 months, p?=?0.017). Within the PTEN-mutant group (n?=?70, 47%), patients treated with TTFields (n?=?14) had longer median PPS (22.2 versus 9.3 months, p?=?0.005). No PPS benefit was observed in PTEN-WT patients receiving TTFields (n?=?79, 53%).TTFields therapy conferred a significant PPS benefit in PTEN-mutant rGBM. Understanding the molecular mechanisms underpinning the differences in response to TTFields therapy could help elucidate the mechanism of action of TTFields and identify the rGBM patients most likely to benefit from this therapeutic option.

View details for DOI 10.1007/s11060-021-03755-1

View details for PubMedID 33881725